ECSP23044286A - Mutaciones en regiones constantes de anticuerpos felinos - Google Patents

Mutaciones en regiones constantes de anticuerpos felinos

Info

Publication number
ECSP23044286A
ECSP23044286A ECSENADI202344286A ECDI202344286A ECSP23044286A EC SP23044286 A ECSP23044286 A EC SP23044286A EC SENADI202344286 A ECSENADI202344286 A EC SENADI202344286A EC DI202344286 A ECDI202344286 A EC DI202344286A EC SP23044286 A ECSP23044286 A EC SP23044286A
Authority
EC
Ecuador
Prior art keywords
mutations
constant regions
feline
feline antibodies
antibodies
Prior art date
Application number
ECSENADI202344286A
Other languages
English (en)
Spanish (es)
Inventor
Lisa Marie Bergeron
Sandra Ann Marie Lightle
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ECSP23044286A publication Critical patent/ECSP23044286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ECSENADI202344286A 2020-12-18 2023-06-14 Mutaciones en regiones constantes de anticuerpos felinos ECSP23044286A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063127313P 2020-12-18 2020-12-18

Publications (1)

Publication Number Publication Date
ECSP23044286A true ECSP23044286A (es) 2023-07-31

Family

ID=79730576

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202344286A ECSP23044286A (es) 2020-12-18 2023-06-14 Mutaciones en regiones constantes de anticuerpos felinos

Country Status (15)

Country Link
US (1) US20240400708A1 (https=)
EP (1) EP4263596A1 (https=)
JP (1) JP2024503212A (https=)
KR (1) KR20230121056A (https=)
CN (1) CN116547298A (https=)
AU (1) AU2021400322A1 (https=)
CA (1) CA3202074A1 (https=)
CL (2) CL2023001781A1 (https=)
CO (1) CO2023007829A2 (https=)
EC (1) ECSP23044286A (https=)
IL (1) IL303732A (https=)
MX (1) MX2023006898A (https=)
PE (1) PE20231640A1 (https=)
TW (1) TW202233687A (https=)
WO (1) WO2022133252A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038522A (ko) 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
WO2022072446A1 (en) 2020-09-29 2022-04-07 Zoetis Services Llc Feline antibody variants
JP2025529206A (ja) * 2022-09-02 2025-09-04 ゾエティス・サービシーズ・エルエルシー 豚抗体変異体
WO2024145280A2 (en) * 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) * 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1553975B8 (en) * 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005037867A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20110123440A1 (en) * 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US20110081347A1 (en) * 2008-06-04 2011-04-07 Macrogenics, Inc. Antibodies with Altered Binding to FcRn and Methods of Using Same
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
JP7536294B2 (ja) * 2018-12-05 2024-08-20 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
KR20230038522A (ko) * 2020-07-10 2023-03-20 인베티엑스 인코포레이티드 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법

Also Published As

Publication number Publication date
WO2022133252A1 (en) 2022-06-23
IL303732A (en) 2023-08-01
CN116547298A (zh) 2023-08-04
AU2021400322A9 (en) 2024-10-24
CL2024001519A1 (es) 2024-08-23
TW202233687A (zh) 2022-09-01
CO2023007829A2 (es) 2023-07-21
EP4263596A1 (en) 2023-10-25
CA3202074A1 (en) 2022-06-23
CL2023001781A1 (es) 2023-12-22
US20240400708A1 (en) 2024-12-05
MX2023006898A (es) 2023-06-26
KR20230121056A (ko) 2023-08-17
PE20231640A1 (es) 2023-10-16
AU2021400322A1 (en) 2023-06-22
JP2024503212A (ja) 2024-01-25

Similar Documents

Publication Publication Date Title
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
CL2023003376A1 (es) Variantes de anticuerpos felinos
CL2023003377A1 (es) Variantes de anticuerpos caninos
ECSP23030271A (es) Variantes de anticuerpos caninos
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
CO2023007146A2 (es) Variantes de anticuerpos bovinos
CL2024000789A1 (es) Variantes de anticuerpos felinos.
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
PE20141060A1 (es) Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
CR20200404A (es) Anticuerpos anti-klk5 y métodos de uso
CL2025004153A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso.
MX2024006208A (es) Anticuerpo anti-trem2 y usos del mismo.
CL2022003288A1 (es) Anticuerpos anti-hbv y métodos de uso
MX2025002524A (es) Mutantes de anticuerpos equinos
CO2024016060A2 (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
MX2025001433A (es) Mutantes de anticuerpos bovinos
EA202192418A1 (ru) Способы лечения al-амилоидоза